Speculation on 3D printed tissue coming to humans sooner than we think is backed by new pre-clinical findings from 3D bioprinting company Organovo (NASDAQ:ONVO). Though it will still be 3 – 5 years before the U.S. based Organovo apply for clearance of their liver tissue, that is still sooner than perhaps even theFDA牢记。
Pre-clinical trial data shows that3D生物打印肝组织已成功种植到实验室的小鼠中。人肝细胞组织表现出规律的功能，并且在此阶段被探讨为适合器官的斑块。
Signs of success
The liver tissue was studied in-vivo for over a month, detecting function through the presence of 3 human proteins in mice’s blood plasma within one week of the implant surgery.
检测到的白蛋白，α-1-抗胰蛋白酶和纤维蛋白原都是由肝脏生产的所有蛋白质，分别负责与体内营养物质结合水，有助于肺的弹性，并起作用以形成血液凝块。
血管的独立生长和遗传条件的应用
In a statement from Organovo’s preclinical development team, chief strategy officer and executive vice president Eric Michael David explains, ‘Our preclinical data show rapid vascularization and tissue engraftment,’ –meaning that the 3D printed tissue encouraged the growth of blood vessels and fused to mice’s bone marrow.
大卫继续说：“我们看到动物血液中关键人肝蛋白稳定产生的证据，以及关键人类代谢酶的组织染色，'adding that‘the presence of these enzymes provides an important first step in demonstrating the capability of this tissue to treat inborn errors of metabolism.”
代谢是人们继承的医疗状况的关键，例如与囊性纤维化相关的肝病。该试验解释说，正在探索3D印刷细胞作为肝脏代谢物结构的斑块，因此会产生治疗作用。
增加分辨率
The findings, and simultaneous distribution agreement with Japanese biopharmaceutical suppliers Cosmo Bio (JASDAQ:3386), will be music to the ears ofOrganovo’s investorswho have experienced a turbulent 2016.
Organovo完成的工作是3D打印的最新使用吗？在这里获得第一届年度3D印刷行业奖的提名。
特色图显示了3D渲染的肝脏。
